[1] YANG L， ZHANG X， YE M，et al. Aptamer-conjugated nanomaterials and their applications. Adv Drug Deliv Rev， 2011， 63(14-15)： 1361-1370.
[2] PROSKE D， BLANK M， BUHMANN R，et al. Aptamers-basic research， drug development， and clinical applications. Appl Microbiol Biotechnol， 2005， 69(4)： 367-374.
[3] ELLINGTON A D， SZOSTAK J W. In vitro selection of RNA molecules that bind specific ligands. Nature， 1990， 346(6287)： 818-822.
[4] TUERK C， GOLD L. Systematic evolution of ligands by exponential enrichment： RNA ligands to bacteriophage T4 DNA polymerase. Science， 1990， 249(4968)： 505-510.
[5] BUNKA D H， STOCKLEY P G. Aptamers come of age - at last. Nat Rev Microbiol， 2006， 4(8)： 588-596.
[6] SHANGGUAN D， LI Y， TANG Z，et al. Aptamers evolved from live cells as effective molecular probes for cancer study. Proc Natl Acad Sci USA， 2006， 103(32)： 11838-11843.
[7] GUTSAEVA D R， PARKERSON J B， YERIGENAHALLY S D，et al. Inhibition of cell adhesion by anti-P-selectin aptamer： A new potential therapeutic agent for sickle cell disease. Blood， 2011， 117(2)： 727-735.
[8] HUANG Y F， SEFAH K， BAMRUNGSAP S，et al. Selective photothermal therapy for mixed cancer cells using aptamer-conjugated nanorods. Langmuir， 2008， 24(20)： 11860-11865.
[9] YANG C X，GE Z Q.Research and development of aptamers acting as drug targeting carriers. Chin Med Biotechnol(中国医药生物技术)， 2010， 5(4)： 297-299.
YANG L， ZHANG X， YE M，et al. Aptamer-conjugated nanomaterials and their applications. Adv Drug Deliv Rev， 2011， 63(14-15)： 1361-1370.
TAN W， WANG H， CHEN Y，et al. Molecular aptamers for drug delivery. Trends Biotechnol， 2011， 29(12)： 634-640.
ZHANG Y， CHEN Y， HAN D，et al. Aptamers selected by cell-SELEX for application in cancer studies. Bioanalysis， 2010， 2(5)： 907-918.
JAYASENA S D. Aptamers： An emerging class of molecules that rival antibodies in diagnostics. Clin Chem， 1999， 45(9)： 1628-1650.
GROUP E S. Anti-vascular endothelial growth factor therapy for subfoveal choroidal neovascularization secondary to age-related macular degeneration： Phase II study results. Ophthalmology， 2003， 110(5)： 979-986.
RUCKMAN J， GREEN L S， BEESON J，et al. 2′-Fluoropyrimidine RNA-based aptamers to the 165-amino acid form of vascular endothelial growth factor (VEGF165). Inhibition of receptor binding and VEGF-induced vascular permeability through interactions requiring the exon 7-encoded domain. J Biol Chem， 1998， 273(32)： 20556-20567.
DOGGRELL S A. Pegaptanib： The first antiangiogenic agent approved for neovascular macular degeneration. Expert Opin Pharmacother， 2005， 6(8)： 1421-1423.
MONGELARD F， BOUVET P. AS-1411， a guanosine-rich oligonucleotide aptamer targeting nucleolin for the potential treatment of cancer， including acute myeloid leukemia. Curr Opin Mol Ther， 2010， 12(1)： 107-114.
KEEFE A D， PAI S， ELLINGTON A. Aptamers as therapeutics. Nat Rev Drug Discov， 2010， 9(7)： 537-550.
BOUCHARD P R， HUTABARAT R M， THOMPSON K M. Discovery and development of therapeutic aptamers. Annu Rev Pharmacol Toxicol， 2010， 50： 237-257.
EULBERG D， KLUSSMANN S. Spiegelmers： Biostable aptamers. Chembiochem， 2003， 4(10)： 979-983.
FAMULOK M， MAYER G， BLIND M. Nucleic acid aptamers-from selection in vitro to applications in vivo. Acc Chem Res， 2000， 33(9)： 591-599.
CHEN X C， DENG Y L， LIN Y，et al. Quantum dot-labeled aptamer nanoprobes specifically targeting glioma cells. Nanotechnology， 2008， 19(23)： 235105.
KO H Y， CHOI K J， LEE C H，et al. A multimodal nanoparticle-based cancer imaging probe simultaneously targeting nucleolin， integrin alphavbeta 3 and tenascin-C proteins. Biomaterials， 2011， 32(4)： 1130-1138.
SUN Z， WANG Y， WEI Y，et al. Ag cluster-aptamer hybrid： Specifically marking the nucleus of live cells. Chem Commun (Camb)， 2011， 47(43)： 11960-11962.
ZUO J M， LI B Q. Nanostructure evolution during cluster growth： Ag on H-terminated Si(111) surfaces. Phys Rev Lett， 2002， 88(25 Pt 1)： 255502.
HUANG Y F， SHANGGUAN D， LIU H，et al. Molecular assembly of an aptamer-drug conjugate for targeted drug delivery to tumor cells. Chembiochem， 2009， 10(5)： 862-868.
CHU T C， MARKS J R， LAVERY L A，et al. Aptamer： Toxin conjugates that specifically target prostate tumor cells. Cancer Res， 2006， 66(12)： 5989-5992.
MEYER C， EYDELER K， MAGBANUA E，et al. Interleukin-6 receptor specific RNA aptamers for cargo delivery into target cells. RNA Biol， 2012， 9(1)： 67-80.
TAN W， WANG H， CHEN Y，et al. Molecular aptamers for drug delivery. Trends Biotechnol， 2011， 29(12)： 634-640.
ZHOU J， LI H， LI S，et al. Novel dual inhibitory function aptamer-siRNA delivery system for HIV-1 therapy. Mol Ther， 2008， 16(8)： 1481-1489.
WULLNER U， NEEF I， ELLER A，et al. Cell-specific induction of apoptosis by rationally designed bivalent aptamer-siRNA transcripts silencing eukaryotic elongation factor 2. Curr Cancer Drug Targets， 2008， 8(7)： 554-565.
MCNAMARA J N， ANDRECHEK E R， WANG Y，et al. Cell type-specific delivery of siRNAs with aptamer-siRNA chimeras. Nat Biotechnol， 2006， 24(8)： 1005-1015.
CAO Z， TONG R， MISHRA A，et al. Reversible cell-specific drug delivery with aptamer-functionalized liposomes. Angew Chem Int Ed Engl， 2009， 48(35)： 6494-6498.
MANN A P， BHAVANE R C， SOMASUNDERAM A，et al. Thioaptamer conjugated liposomes for tumor vasculature targeting. Oncotarget， 2011， 2(4)： 298-304.
KATAOKA K， HARADA A， NAGASAKI Y. Block copolymer micelles for drug delivery： Design， characterization and biological significance. Adv Drug Deliv Rev， 2001， 47(1)： 113-131.
WU Y， SEFAH K， LIU H，et al. DNA aptamer-micelle as an efficient detection/delivery vehicle toward cancer cells. Proc Natl Acad Sci USA， 2010， 107(1)： 5-10.
PING S， LAI C. AS1411 Aptamer-conjudated polymeric micelle for targetable cancer therapy. NSTI-Nanotech， 2010，(3)： 330-333.
MATHEW A， ARAVIND A， BRAHATHEESWARAN D，et al. Amyloid-binding aptamer conjugated curcumin-PLGA aanoparticle for potential use in alzheimer′s disease. Bio Nano Sci， 2012，2（2）：83-93.
GUO J， GAO X， SU L，et al. Aptamer-functionalized PEG-PLGA nanoparticles for enhanced anti-glioma drug delivery. Biomaterials， 2011， 32(31)： 8010-8120.
GAO H， QIAN J， CAO S，et al. Precise glioma targeting of and penetration by aptamer and peptide dual-functioned nanoparticles. Biomaterials， 2012， 33(20)： 5115-5123.
ZHOU J， ROSSI J J. Cell-specific aptamer-mediated targeted drug delivery. Oligonucleotides， 2011， 21(1)： 1-10.
VAN DEN BOSSCHE J， AL-JAMAL W T， TIAN B，et al. Efficient receptor-independent intracellular translocation of aptamers mediated by conjugation to carbon nanotubes. Chem Commun (Camb)， 2010， 46(39)： 7379-7381.
KANG H， TRONDOLI A C， ZHU G，et al. Near-infrared light-responsive core-shell nanogels for targeted drug delivery. ACS Nano， 2011， 5(6)： 5094-5099.